Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onradivir - Guangdong Raynovent Biotech

Next Previous
Drug Profile

Onradivir - Guangdong Raynovent Biotech

Alternative Names: ZSP-1273

Latest Information Update: 24 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangdong Raynovent Biotech
  • Class 2 ring heterocyclic compounds; Amines; Antivirals; Bridged bicyclo compounds; Carboxylic acids; Cyclopropanes; Fluorinated hydrocarbons; Pyrazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Influenzavirus A PB2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Influenza A virus infections

Most Recent Events

  • 21 Nov 2025 Guangdong Raynovent Biotech plans a phase III trial in Influenza A virus infections (In children) in China (PO) in November 2025 (NCT07229807)
  • 17 Nov 2025 Phase-III clinical trials in Influenza A virus infections (In adolescents, In children) in China (PO, Tablet) (NCT07229820)
  • 31 Jul 2025 Guangdong Raynovent Biotech completes a phase-II clinical trials in Influenza A virus infections (In children, In adolescents) in China (PO, Granules) (NCT06656026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top